Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia

19Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective: To evaluate levels of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in second trimester amniotic fluid of women with hypertensive disorders compared to normotensive women. Study Design: Amniotic fluid was obtained from 133 women undergoing genetic second trimester amniocentesis. Zymography was performed for MMP characterization and an MMP-2 ELISA kit was used to determine MMP-2 levels. TIMP-2 expression was evaluated using western blot. Results: Mean amniotic fluid MMP-2 and TIMP-2 levels were significantly higher in women who developed a hypertensive disorder compared to normotensive women (P < 0.0004 and P < 0.01, respectively). When subdivided into subgroups, amniotic fluid from women who eventually developed preeclampsia or superimposed preeclampsia showed significantly higher MMP-2 levels than normotensive women (P < 0.05). However, no statistical difference in MMP-2 levels was found between patients with gestational hypertension and normotensive patients. Conclusion: Higher amniotic fluid MMP-2 and TIMP-2 levels are found in women who eventually develop preeclampsia. © 2009 Lavee et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Lavee, M., Goldman, S., Daniel-Spiegel, E., & Shalev, E. (2009). Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia. Reproductive Biology and Endocrinology, 7. https://doi.org/10.1186/1477-7827-7-85

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free